Progression-free survival as a surrogate endpoint for overall survival | OTT
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Early tumor shrinkage improves survival in pancreatic cancer
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
A) Disease-free survival, (B) progression-free survival and (C)... | Download Scientific Diagram
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f33163534f9a85acc25579932597eab0cf9e71ff/7-Figure1-1.png "PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar")
PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar
PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Extrapolation from Progression Free Survival to Overall Survival in O…
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
Cancers | Free Full-Text | Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy
